The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease
Open accessAbstract
BACKGROUND: In adults with sickle cell disease (SCD), an increased tricuspid regurgitant velocity (TRV) measured by Doppler echocardiography, an increased serum N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension (PH) diagnosed by right heart catheterization (RHC) are independent risk factors for mortality. METHODS: A multidisciplinary committee was formed by clinician-investigators experienced in the management of patients with PH and/or SCD. Clinically important questions were posed, related evidence was appraised, and questions were answered with evidence-based recommendations. Target audiences include all clinicians who take care of patients with SCD. RESULTS: Mortality risk stratification guides decision making. An increased risk for mortality is defined as a TRV equal to or greater than 2.5 m/second, an NT-pro-BNP level equal to or greater than 160 pg/ml, or RHC-confirmed PH. For patients identified as having increased mortality risk, we make a strong recommendation for hydroxyurea as first-line therapy and a weak recommendation for chronic transfusions as an alternative therapy. For all patients with SCD with elevated TRV alone or elevated NT-pro-BNP alone, and for patients with SCD with RHC-confirmed PH with elevated pulmonary artery wedge pressure and low pulmonary vascular resistance, we make a strong recommendation against PAH-specific therapy. However, for select patients with SCD with RHC-confirmed PH who have elevated pulmonary vascular resistance and normal pulmonary capillary wedge pressure, we make a weak recommendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong recommendation against phosphodiesterase-5 inhibitor therapy. CONCLUSIONS: Evidence-based recommendations for the management of patients with SCD with increased mortality risk are provided, but will require frequent reassessment and updating.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Self-citationD'Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,501
Self-citationACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Self-citationEffect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Adams, R. J., McKie, V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390102 · Cited by 1,866
Self-citationPulmonary Hypertension in Heart Failure With Preserved Ejection Fraction
Lam, C. S. P., Roger, V. L., Rodeheffer, R. J., Borlaug, B. A., Enders, F. T., & Redfield, M. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.051 · Cited by 1,341
Dams, R. O. J. A., Ie, V. I. C. M. C. K., Su, L. E. H., Iles, B. E. F., Ichinsky, E. L. V., Egelow, C. H. P., Bboud, M. I. A., Allagher, D. I. G., Utlar, K., Ichols, F. E. T. N., et al. (2015) · Cited by 1,338
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationCauses and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease
Vichinsky, E. P., Neumayr, L. D., Earles, A. N., Williams, R., Lennette, E. T., Dean, D., Nickerson, B., Orringer, E., McKie, V., Bellevue, R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422502 · Cited by 1,234
Writing Committee Members, McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,093
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 931
Self-citationLong-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Wang, W. C., Ware, R. E., Miller, S. T., Iyer, R. V., Casella, J. F., Minniti, C. P., Rana, S., Thornburg, C. D., Rogers, Z. R., Kalpatthi, R. V., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60355-3 · Cited by 803 · cited 15×
“Therefore, Doppler echocardiography should be performed when the patient is in a stable clinical state, defined as more than 4 weeks after hospitalization for ACS and more than 2 weeks after hospitalization for a VOC or a blood transfusion that is part of a chronic transfusion program.”
BackgroundInfluentialDiscontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa050460 · Cited by 635
d -Dimer Testing to Determine the Duration of Anticoagulation Therapy
Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054444 · Cited by 622
The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism
Schulman, S., Granqvist, S., Holmström, M., Carlsson, A., Lindmarker, P., Nicol, P., Eklund, S.-G., Nordlander, S., Lärfars, G., Leijd, B., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702063360601 · Cited by 604
Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course
Vichinsky, E. P., Styles, L. A., Colangelo, L. H., Wright, E. C., Castro, O., Nickerson, B., & Disease, T. C. S. O. S. C. (1997) · Blood · doi:10.1182/blood.v89.5.1787 · Cited by 573
Self-citationGuazzi, M., Vicenzi, M., Arena, R., & Guazzi, M. D. (2011) · Circulation · doi:10.1161/circulationaha.110.983866 · Cited by 545
A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease
Parent, F., Bachir, D., Inamo, J., Lionnet, F., Driss, F., Loko, G., Habibi, A., Bennani, S., Savale, L., Adnot, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005565 · Cited by 512
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486
Self-citationPulmonary Complications of Sickle Cell Disease
Gladwin, M. T., & Vichinsky, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0804411 · Cited by 470
Self-citationPulmonary hypertension in chronic obstructive pulmonary disease
Barberà, J. A., Peinado, V. I., & Santos, S. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00115402 · Cited by 449
Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival
Castro, O., Hoque, M., & Brown, B. D. (2003) · Blood · doi:10.1182/blood-2002-03-0948 · Cited by 327
Self-citationStroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results
Lee, M. T., Piomelli, S., Granger, S., Miller, S. T., Harkness, S., Brambilla, D. J., Adams, R. J., & for the STOP Study Investigators (2006) · Blood · doi:10.1182/blood-2005-10-009506 · Cited by 319
Falk, R. J., Scheinman, J., Phillips, G., Orringer, E., Johnson, A., & Jennette, J. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204023261402 · Cited by 300
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study
Ataga, K. I., Moore, C. G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A., & Orringer, E. P. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06110.x · Cited by 298 · cited 1×
“Longitudinal studies of adults with SCD suggest that 13% of those with a normal echocardiogram develop an elevated TRV after approximately 3 years of follow-up (5).”
BackgroundSelf-citationHydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial
Ferster, A., Vermylen, C., Cornu, G., Buyse, M., Corazza, F., Devalck, C., Fondu, P., Toppet, M., & Sariban, E. (1996) · Blood · doi:10.1182/blood.v88.6.1960.bloodjournal8861960 · Cited by 279
Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease
Fonseca, G. H. H., Souza, R., Salemi, V. M. C., Jardim, C. V. P., & Gualandro, S. F. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00134410 · Cited by 274
Brawley, O. W., Cornelius, L. J., Edwards, L. R., Gamble, V. N., Green, B. L., Inturrisi, C., James, A. H., Laraque, D., Mendez, M., Montoya, C. J., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-12-200806170-00220 · Cited by 272
Anthi, A., Machado, R. F., Jison, M. L., Taveira-DaSilva, A. M., Rubin, L. J., Hunter, L., Hunter, C. J., Coles, W., Nichols, J., Avila, N. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200610-1498oc · Cited by 270
Self-citationCauses of death in sickle-cell disease in Jamaica.
Thomas, A. N., Pattison, C., & Serjeant, G. R. (1982) · BMJ · doi:10.1136/bmj.285.6342.633 · Cited by 266
Machado, R. F., Barst, R. J., Yovetich, N. A., Hassell, K. L., Kato, G. J., Gordeuk, V. R., Gibbs, J. S. R., Little, J. A., Schraufnagel, D. E., Krishnamurti, L., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306167 · Cited by 250
Self-citationPulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Patel, N. M., Lederer, D. J., Borczuk, A. C., & Kawut, S. M. (2007) · Chest · doi:10.1378/chest.06-3087 · Cited by 248
De Castro, L. M., Jonassaint, J. C., Graham, F. L., Ashley‐Koch, A., & Telen, M. J. (2008) · American Journal of Hematology · doi:10.1002/ajh.21058 · Cited by 243
Self-citationPortopulmonary Hypertension: Survival and Prognostic Factors
Le Pavec, J., Souza, R., Herve, P., Lebrec, D., Savale, L., Tcherakian, C., Jaïs, X., Yaïci, A., Humbert, M., Simonneau, G., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200804-613oc · Cited by 241
Miller, S. T., Wright, E., Abboud, M., Berman, B., Files, B., Scher, C. D., Styles, L., & Adams, R. J. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.119593 · Cited by 238
Mortality in Adults With Sickle Cell Disease and Pulmonary Hypertension
Mehari, A., Gladwin, M. T., Tian, X., Machado, R. F., & Kato, G. J. (2012) · JAMA · doi:10.1001/jama.2012.358 · Cited by 229 · cited 1×
“Pulmonary hypertension (PH) is common and associated with increased morbidity and mortality in sickle cell disease (SCD) (1, 2).”
BackgroundSelf-citationPulmonary Diseases and the Heart
Han, M. K., McLaughlin, V. V., Criner, G. J., & Martinez, F. J. (2007) · Circulation · doi:10.1161/circulationaha.106.685206 · Cited by 215
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension
Machado, R. F., Martyr, S., Kato, G. J., Barst, R. J., Anthi, A., Robinson, M. R., Hunter, L., Coles, W., Nichols, J., Hunter, C., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05625.x · Cited by 212
Self-citationDeep Venous Thrombosis and Pulmonary Embolism in Hospitalized Patients with Sickle Cell Disease
Stein, P. D., Beemath, A., Meyers, F. A., Skaf, E., & Olson, R. E. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.015 · Cited by 203
N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease
Machado, R. F., Anthi, A., Steinberg, M. H., Bonds, D., Sachdev, V., Kato, G. J., Taveira-DaSilva, A. M., Ballas, S. K., Blackwelder, W., Xu, X., et al. (2006) · JAMA · doi:10.1001/jama.296.3.310 · Cited by 197
Self-citationCoagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension
Ataga, K. I., Moore, C. G., Hillery, C. A., Jones, S., Whinna, H. C., Strayhorn, D., Sohier, C., Hinderliter, A., Parise, L. V., & Orringer, E. P. (2008) · Haematologica · doi:10.3324/haematol.11763 · Cited by 187
Self-citationEndothelin receptor antagonists for pulmonary arterial hypertension
Liu, C., Chen, J., Gao, Y., Deng, B., & Liu, K. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004434.pub5 · Cited by 181
Hydroxyurea and sickle cell anemia: effect on quality of life
Ballas, S. K., Barton, F. B., Waclawiw, M. A., Swerdlow, P., Eckman, J. R., Pegelow, C. H., Koshy, M., Barton, B. A., & Bonds, D. R. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-59 · Cited by 166
Sachdev, V., Kato, G. J., Gibbs, J. S. R., Barst, R. J., Machado, R. F., Nouraie, M., Hassell, K. L., Little, J. A., Schraufnagel, D. E., Krishnamurti, L., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.032920 · Cited by 147
Self-citationPulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies
Collins, F. S., & Orringer, E. P. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90763-x · Cited by 142
Barst, R. J., Mubarak, K. K., Machado, R. F., Ataga, K. I., Benza, R. L., Castro, O. L., Naeije, R., Sood, N., Swerdlow, P. S., Hildesheim, M. E., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08097.x · Cited by 136
Self-citationHemodynamic Predictors of Mortality in Adults with Sickle Cell Disease
Mehari, A., Alam, S., Tian, X., Cuttica, M. J., Barnett, C. F., Miles, G., Xu, D., Seamon, C., Adams-Graves, P., Castro, O. L., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1222oc · Cited by 135
Self-citationMachado, R. F., Mack, A. K., Martyr, S. E., Barnett, C. F., MacArthur, P. H., Sachdev, V., Ernst, I., Hunter, L. A., Coles, W. A., Nichols, J., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06417.x · Cited by 127
Self-citationDerchi, G., Forni, G. L., Formisano, F., Cappellini, Galanello, R., D'Ascola, G., Bina, P., Magnano, C., & Lamagna, M. (2005) · PubMed · Cited by 125
Barnett, C. F., Hsue, P. Y., & Machado, R. F. (2008) · JAMA · doi:10.1001/jama.299.3.324 · Cited by 117
Self-citationPULMONARY HYPERTENSION IN SICKLE CELL DISEASE: Relevance to Children
Kato, G. J., Onyekwere, O. C., & Gladwin, M. T. (2007) · Pediatric Hematology and Oncology · doi:10.1080/08880010601185892 · Cited by 116
Self-citationAmbrusko, S. J., Gunawardena, S. W., Sakara, A., Windsor, B., Lanford, L. M., Michelson, P. H., & Krishnamurti, L. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20791 · Cited by 115
Self-citationExposure to Hydroxyurea and Pregnancy Outcomes in Patients With Sickle Cell Anemia
Ballas, S. K., McCarthy, W. F., Guo, N., DeCastro, L. M., Bellevue, R., BARTON, B. A., & Waclawiw, M. A. (2009) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)31072-5 · Cited by 111
Self-citationPulmonary Complications of Sickle Cell Anemia
Minter, K. R., & Gladwin, M. T. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.11.2104101 · Cited by 102
Self-citationGordeuk, V. R., Minniti, C. P., Nouraie, M. S., Campbell, A., RANA, S. R., Luchtman‐Jones, L., Sable, C., Dham, N., Ensing, G. J., Prchal, J. T., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.030767 · Cited by 90
Self-citationLezcano, N. E., Odo, N., Kutlar, A., Brambilla, D. J., & Adams, R. J. (2006) · Stroke · doi:10.1161/01.str.0000221173.97108.01 · Cited by 88
Minniti, C. P., Machado, R. F., Coles, W. A., Sachdev, V., Gladwin, M. T., & Kato, G. J. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07906.x · Cited by 81
Self-citationWang, W. C., Morales, K. H., Scher, C. D., Styles, L. A., Olivieri, N. F., Adams, R. J., & Brambilla, D. J. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.02.030 · Cited by 80
Voskaridou, E., Tsetsos, G. A., Tsoutsias, A., Spyropoulou, E., Christoulas, D., & Terpos, E. (2007) · Haematologica · doi:10.3324/haematol.11136 · Cited by 69
Machado, R. F., Hildesheim, M. E., Mendelsohn, L. G., Remaley, A. T., Kato, G. J., & Gladwin, M. T. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08777.x · Cited by 66
Self-citationLongitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease
Pashankar, F., Carbonella, J., Bazzy‐Asaad, A., & Friedman, A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07501.x · Cited by 62
Files, B. A., Brambilla, D. J., Kutlar, A., Miller, S., Vichinsky, E. P., Wang, W. C., Granger, S., & Adams, R. J. (2002) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200205000-00013 · Cited by 62
Pulmonary Arterial Hypertension Complicating Connective Tissue Diseases
Hassoun, P. M. (2009) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0029-1233312 · Cited by 61
Prostacyclin for pulmonary hypertension in adults
Paramothayan, N. S., Lasserson, T. J., Wells, A. U., & Walters, E. H. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002994.pub2 · Cited by 53
Klings, E. S., Bland, D. A., Rosenman, D., Princeton, S., Odhiambo, A., Li, G., Bernard, S. A., Steinberg, M. H., & Farber, H. W. (2008) · American Journal of Hematology · doi:10.1002/ajh.21187 · Cited by 52
Self-citationMorris, C. R. (2006) · Treatments in Respiratory Medicine · doi:10.2165/00151829-200605010-00003 · Cited by 50
Self-citationOlnes, M. J., Chi, A., Haney, C., May, R., Minniti, C. P., Taylor, J. G., & Kato, G. J. (2009) · American Journal of Hematology · doi:10.1002/ajh.21446 · Cited by 47
Self-citationPulmonary Hypertension in COPD: A Review and Consideration of the Role of Arterial Vasodilators
Burger, C. D. (2009) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550902754252 · Cited by 47
No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension
van Beers, E. J., Spronk, H. M. H., Cate, H. T., Duits, A. J., Brandjes, D. P. M., van Esser, J. W. J., Biemond, B. J., Schnog, J. B., & on behalf of the CURAMA study Group (2008) · Haematologica · doi:10.3324/haematol.12632 · Cited by 39
Blood transfusion for preventing stroke in people with sickle cell disease
Hirst, C., & Wang, W. C. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003146 · Cited by 26
Fitzgerald, M., Fagan, K., Herbert, D. E., Al-Ali, M., Mugal, M., & Haynes, J. (2012) · Southern Medical Journal · doi:10.1097/smj.0b013e318256b55b · Cited by 25
Pulmonary hypertension in sickle cell disease.
Castro, O. L., Minniti, C. P., & Nouraie, M. S. (2011) · PubMed · doi:10.1056/nejmc1109130 · Cited by 12
Self-citation
Research works printed but not linked: 3
- Claster, 1999, Treatment of pulmonary hypertension in sickle cell disease with transfusion [abstract], Blood, 94, 420A
- Lisbona, 1997, Scintigraphic evidence of pulmonary vascular occlusion in sickle cell disease, J Nucl Med, 38, 1151
- Kanthapillai, 2004, Sildenafil for pulmonary hypertension, Cochrane Database Syst Rev, CD003562
Cited by
Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members
Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., Jordan, L., Lanzkron, S. M., Lottenberg, R., Savage, W. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.10517 · Cited by 1,599
Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Self-citationPathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Self-citationBiologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease
Kanter, J., Walters, M. C., Krishnamurti, L., Mapara, M. Y., Kwiatkowski, J. L., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Pierciey, F. J., Bonner, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117175 · Cited by 442
Self-citationCardiovascular complications and risk of death in sickle-cell disease
Gladwin, M. T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00647-4 · Cited by 164
Self-citation
Metadata
- Authors
- Klings, E. S., Machado, R. F., Barst, R. J., Morris, C. R., Mubarak, K. K., Gordeuk, V. R., Kato, G. J., Ataga, K. I., Gibbs, J. S., Castro, O., Rosenzweig, E. B., Sood, N., Hsu, L., Wilson, K. C., Telen, M. J., DeCastro, L. M., Krishnamurti, L., Steinberg, M. H., Badesch, D. B., & Gladwin, M. T.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-15
- Volume
- 189
- Issue
- 6
- Pages
- 727-740
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2123161963
- Cited by
- 263
- References
- 75
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.